<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-9012eb811c2dd1ecac0d7c42f51fb3329b35393b8f3b810b34a005351de74f32">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?items_per_page_toggle=1&amp;page=3&amp;order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?items_per_page_toggle=1&amp;page=3&amp;order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-06-25T17:44:00Z" timezone="America/New_York" class="datetime">Jun 25, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-new-portfolio-reimbursement-agreement-italy" hreflang="en">Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Reimbursement agreement also includes certain future indication extensions across all Vertex CF medicines - - Approximately 1,400 patients will now have access to a CFTR modulator for the first time - LONDON --(BUSINESS WIRE)--Jun. 25, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-new-portfolio-reimbursement-agreement-italy" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28541/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-06-18T19:37:00Z" timezone="America/New_York" class="datetime">Jun 18, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/health-canada-grants-marketing-authorization-trikaftar" hreflang="en">Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA ®
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/health-canada-grants-marketing-authorization-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28531/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-06-11T07:05:00Z" timezone="America/New_York" class="datetime">Jun 11, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-22-patients" hreflang="en">Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion - BOSTON &amp;amp; ZUG, Switzerland &amp;amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-22-patients" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/d943ce5b-7413-4ebf-9382-78cee71a9895" type="application/pdf" title="CRSP 2021 6-11-2021 PR.pdf">PDF Version</a></span><span class="filesize"> 577.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-06-10T20:03:00Z" timezone="America/New_York" class="datetime">Jun 10, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-primary-endpoint-achieved-phase-2-study-vx-864" hreflang="en">Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide proof-of-mechanism, although magnitude of treatment effect observed unlikely to translate into substantial
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-primary-endpoint-achieved-phase-2-study-vx-864" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28516/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-06-09T12:00:00Z" timezone="America/New_York" class="datetime">Jun 9, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-trikaftar" hreflang="en">Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28496/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-05-12T15:00:00Z" timezone="America/New_York" class="datetime">May 12, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-clinical-data" hreflang="en">Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) --&amp;nbsp; Vertex Pharmaceuticals Incorporated &amp;nbsp;(Nasdaq: VRTX) and&amp;nbsp; CRISPR Therapeutics &amp;nbsp;(Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-clinical-data" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28446/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-05-10T13:01:00Z" timezone="America/New_York" class="datetime">May 10, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-bank-america-securities-2021-virtual-health-care" hreflang="en">Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--May 10, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-bank-america-securities-2021-virtual-health-care" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28436/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-29T20:01:00Z" timezone="America/New_York" class="datetime">Apr 29, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2021-financial-results" hreflang="en">Vertex Reports First-Quarter 2021 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Product revenues of $1.72 billion , a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON --(BUSINESS WIRE)--Apr.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2021-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28361/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-28T11:30:00Z" timezone="America/New_York" class="datetime">Apr 28, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kaftrior" hreflang="en">Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type - - People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy - LONDON --(BUSINESS WIRE)--Apr.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kaftrior" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28346/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-26T12:30:00Z" timezone="America/New_York" class="datetime">Apr 26, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-priority-medicines-prime" hreflang="en">Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia </a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex &amp;nbsp;Pharmaceuticals Incorporated (Nasdaq: VRTX) and&amp;nbsp; CRISPR Therapeutics &amp;nbsp;(Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-priority-medicines-prime" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28341/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-26T11:29:00Z" timezone="America/New_York" class="datetime">Apr 26, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-nav18-inhibitor-advancing-phase-2-clinical" hreflang="en">Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Proof-of-concept studies of VX-548 in acute pain to initiate in the second half of the year - BOSTON --(BUSINESS WIRE)--Apr. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective   NaV1.8 inhibitor, VX-548, into Phase 2 clinical
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-nav18-inhibitor-advancing-phase-2-clinical" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28336/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-22T12:00:00Z" timezone="America/New_York" class="datetime">Apr 22, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-obsidian-therapeutics-establish-collaboration" hreflang="en">Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases - Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones BOSTON &amp;amp; CAMBRIDGE,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-obsidian-therapeutics-establish-collaboration" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28331/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-20T11:15:00Z" timezone="America/New_York" class="datetime">Apr 20, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-pharmaceuticals-and-crispr-therapeutics-amend" hreflang="en">Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CRISPR to receive $900 million upfront payment with potential for additional $200 million
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-pharmaceuticals-and-crispr-therapeutics-amend" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28321/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-04-19T13:01:00Z" timezone="America/New_York" class="datetime">Apr 19, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-first-quarter-2021-financial-results-april-29" hreflang="en">Vertex to Announce First-Quarter 2021 Financial Results on April 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-first-quarter-2021-financial-results-april-29" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28311/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-03-26T11:23:00Z" timezone="America/New_York" class="datetime">Mar 26, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-kaftrior" hreflang="en">Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - If approved, people ages 12 years and older who have one copy of the F508del mutation and a gating (F/G) or residual function (F/RF) mutation will now be eligible for triple combination therapy - LONDON --(BUSINESS WIRE)--Mar. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-kaftrior" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28271/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-03-24T23:21:00Z" timezone="America/New_York" class="datetime">Mar 24, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-australian-tga-approval-trikaftar" hreflang="en">Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - LONDON --(BUSINESS WIRE)--Mar. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-australian-tga-approval-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28266/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-03-10T12:55:00Z" timezone="America/New_York" class="datetime">Mar 10, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-fast-track-designation-and-initiation-phase" hreflang="en">Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes – – VX-880 is the first and only pancreatic islet replacement therapy known to receive Fast Track Designation – BOSTON
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-fast-track-designation-and-initiation-phase" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28261/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-02-24T14:01:00Z" timezone="America/New_York" class="datetime">Feb 24, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-2" hreflang="en">Vertex to Present at the Cowen Health Care Conference on March 2</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Feb. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET . The audio portion of management&#039;s remarks will be available live through Vertex
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-2" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/28196/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-02-01T21:01:00Z" timezone="America/New_York" class="datetime">Feb 1, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2020-financial" hreflang="en">Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Full-year 2020 GAAP product revenues of $6.20 billion - -Full-year 2020 non-GAAP product revenues of $6.20 billion , a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion - BOSTON --(BUSINESS WIRE)--Feb.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2020-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27971/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-01-28T21:11:00Z" timezone="America/New_York" class="datetime">Jan 28, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug-ind" hreflang="en">Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - BOSTON --(BUSINESS WIRE)--Jan. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug-ind" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27956/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-01-26T13:30:00Z" timezone="America/New_York" class="datetime">Jan 26, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-us-fda-acceptance-supplemental-new-drug" hreflang="en">Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -FDA grants Priority Review of the application and sets a PDUFA target action date of June 8, 2021 - BOSTON --(BUSINESS WIRE)--Jan. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-us-fda-acceptance-supplemental-new-drug" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27951/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-01-22T14:01:00Z" timezone="America/New_York" class="datetime">Jan 22, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-fourth-quarter-2020-financial-results-february-1" hreflang="en">Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-fourth-quarter-2020-financial-results-february-1" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27941/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2021-01-07T14:01:00Z" timezone="America/New_York" class="datetime">Jan 7, 2021</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-11" hreflang="en">Vertex to Present at the J.P. Morgan Healthcare Conference on January 11</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET ( 6:10 a.m. PT ). The audio portion of management’s remarks can be accessed
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-11" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27916/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-12-28T13:00:00Z" timezone="America/New_York" class="datetime">Dec 28, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-new-drug-submission-investigational-triple" hreflang="en">Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON , Dec. 28, 2020 /CNW/ -  Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced its New Drug Submission for TRIKAFTA®, Vertex &#039;s investigational triple combination medicine, has been accepted for Priority Review by Health Canada for the treatment of cystic fibrosis (CF) in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-new-drug-submission-investigational-triple" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27906/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-12-22T13:30:00Z" timezone="America/New_York" class="datetime">Dec 22, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/skyhawk-and-vertex-establish-strategic-collaboration-discover" hreflang="en">Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Vertex receives exclusive options to license a number of Skyhawk’s product candidates directed at serious diseases Skyhawk receives $40 million upfront as well as potential milestones and royalty payments on future sales WALTHAM, Mass. &amp;amp; BOSTON --(BUSINESS WIRE)--Dec.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/skyhawk-and-vertex-establish-strategic-collaboration-discover" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27901/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-12-21T19:30:00Z" timezone="America/New_York" class="datetime">Dec 21, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-approvals-trikaftar" hreflang="en">Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - More than 600 people with certain rare CF mutations are now eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Dec. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA ®
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-approvals-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27896/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-12-05T17:30:00Z" timezone="America/New_York" class="datetime">Dec 5, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-present-new-data-investigational" hreflang="en">CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion - - Sickle cell disease: All three patients were free of vaso-occlusive crises with 3 to 15 months of follow-up after CTX001 infusion - - Nineteen patients have been dosed with
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-present-new-data-investigational" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27886/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-12-01T14:00:00Z" timezone="America/New_York" class="datetime">Dec 1, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-host-investor-webcast-review-data" hreflang="en">CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-host-investor-webcast-review-data" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27871/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-11-27T08:00:00Z" timezone="America/New_York" class="datetime">Nov 27, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-symkevir" hreflang="en">Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - The combination therapy is a new treatment option for CF patients who are homozygous for F508del - - The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations - LONDON --(BUSINESS WIRE)--Nov.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-symkevir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27866/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-11-13T21:01:00Z" timezone="America/New_York" class="datetime">Nov 13, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-recommends-rejection-mini-tender-offer-trc-capital" hreflang="en">Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited “mini-tender” offer dated November 9, 2020 , made by TRC Capital Investment Corporation , an Ontario, Canada , corporation to purchase up to
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-recommends-rejection-mini-tender-offer-trc-capital" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27831/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-11-12T21:01:00Z" timezone="America/New_York" class="datetime">Nov 12, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-jefferies-virtual-london-health-care-conference" hreflang="en">Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Nov. 12, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual London Health Care Conference on Thursday, November 19, 2020 at 9:05 a.m. ET ( 2:05 p.m. GMT ).
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-jefferies-virtual-london-health-care-conference" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27826/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-11-05T09:00:00Z" timezone="America/New_York" class="datetime">Nov 5, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-2" hreflang="en">Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe - LONDON --(BUSINESS WIRE)--Nov. 5, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-2" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27801/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-11-04T14:20:00Z" timezone="America/New_York" class="datetime">Nov 4, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crisprcas9-gene-editing-therapy-ctx001tm-severe" hreflang="en">CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crisprcas9-gene-editing-therapy-ctx001tm-severe" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27796/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-10-29T20:01:00Z" timezone="America/New_York" class="datetime">Oct 29, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2020-financial-results" hreflang="en">Vertex Reports Third-Quarter 2020 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Product revenues of $1.54 billion , a 62% increase compared to Q3 2019- -Company raises revenue guidance; now expects 2020 product revenues of $6.0 to $6.2 billion - BOSTON --(BUSINESS WIRE)--Oct. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2020-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27781/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-10-19T20:01:00Z" timezone="America/New_York" class="datetime">Oct 19, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2020-financial-results-october-29" hreflang="en">Vertex to Announce Third-Quarter 2020 Financial Results on October 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Oct. 19, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2020-financial-results-october-29" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27751/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-10-14T20:30:00Z" timezone="America/New_York" class="datetime">Oct 14, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-provides-update-its-clinical-programs-targeting-alpha-1" hreflang="en">Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 - - AATD research program continues to progress - BOSTON --(BUSINESS
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-provides-update-its-clinical-programs-targeting-alpha-1" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27746/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-25T12:00:00Z" timezone="America/New_York" class="datetime">Sep 25, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator-0" hreflang="en">FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Approval provides opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from a cohort of the Phase 3 ARRIVAL study support treatment with KALYDECO in children ages four to 
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27736/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-24T09:25:00Z" timezone="America/New_York" class="datetime">Sep 24, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-new-data-european-and-north-american-virtual" hreflang="en">Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Oral presentation of interim results from TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) open-label safety extension study to be presented at the ECFS Digital Conference - - Six presentations highlighting data from KALYDECO ® (ivacaftor), ORKAMBI ® (lumacaftor/ivacaftor) and TRIKAFTA
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-new-data-european-and-north-american-virtual" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27731/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-22T13:01:00Z" timezone="America/New_York" class="datetime">Sep 22, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-pharmaceuticals-announce-priority" hreflang="en">CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Inco r porated &amp;nbsp;(Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-pharmaceuticals-announce-priority" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27726/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-16T20:30:00Z" timezone="America/New_York" class="datetime">Sep 16, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/moderna-and-vertex-establish-new-collaboration-treat-cystic" hreflang="en">Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Second collaboration between Moderna and Vertex based on Moderna’s proprietary mRNA and LNP technology Collaboration will leverage Vertex’s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/moderna-and-vertex-establish-new-collaboration-treat-cystic" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27716/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-14T08:15:00Z" timezone="America/New_York" class="datetime">Sep 14, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-medicines-agency-type-ii-variation" hreflang="en">Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Sep. 14, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO ®* (ivacaftor/tezacaftor/elexacaftor)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-medicines-agency-type-ii-variation" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27711/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-10T13:00:00Z" timezone="America/New_York" class="datetime">Sep 10, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-phase-3-study-trikaftar" hreflang="en">Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Sep. 10, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)   in children ages 6 through 11 years old with cystic fibrosis (CF) who have
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-phase-3-study-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27706/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-10T07:57:00Z" timezone="America/New_York" class="datetime">Sep 10, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-foundation-announces-eu1-million-donation-ronald-mcdonald" hreflang="en">The Vertex Foundation Announces €1 Million Donation to Ronald McDonald House Charities at the New Children’s Hospital in Ireland</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Sep. 10, 2020-- The Vertex Foundation , a nonprofit charitable foundation, today announced a €1 million donation to Ronald McDonald House Charities (RMHC) to support the construction of a Ronald McDonald House at the new children’s hospital in Dublin, Ireland .
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-foundation-announces-eu1-million-donation-ronald-mcdonald" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27701/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-09-01T13:00:00Z" timezone="America/New_York" class="datetime">Sep 1, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-accepts-vertexs-supplemental-new-drug-applications-trikaftar" hreflang="en">FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - More than 600 people with certain rare CF mutations could become newly eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Sep. 1, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-accepts-vertexs-supplemental-new-drug-applications-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27691/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-08-21T13:07:00Z" timezone="America/New_York" class="datetime">Aug 21, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/european-commission-approves-kaftrior" hreflang="en">European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – For the first time, up to 10,000 people in Europe ages 12 years and older with one F508del mutation and one minimal function mutation will be eligible for a medicine that treats the underlying cause of cystic fibrosis – – People 12 years of age and older who have two F508del mutations will also
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/european-commission-approves-kaftrior" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27681/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-07-30T20:01:00Z" timezone="America/New_York" class="datetime">Jul 30, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2020-financial-results" hreflang="en">Vertex Reports Second-Quarter 2020 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Product revenues of $1.52 billion , a 62% increase compared to Q2 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.7 to $5.9 billion - BOSTON --(BUSINESS WIRE)--Jul. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2020-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27616/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-07-20T13:00:00Z" timezone="America/New_York" class="datetime">Jul 20, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/positive-phase-3-study-results-trikaftar" hreflang="en">Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Phase 3 study met primary endpoint and all secondary endpoints- -Study is a U.S. post-marketing commitment and will be submitted to FDA- -Data also will be submitted to the European Medicines Agency to support indication expansion of the EU label following triple combination approval- BOSTON
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/positive-phase-3-study-results-trikaftar" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27601/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-07-16T13:00:00Z" timezone="America/New_York" class="datetime">Jul 16, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2020-financial-results-july-30" hreflang="en">Vertex to Announce Second-Quarter 2020 Financial Results on July 30</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jul. 16, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2020-financial-results-july-30" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27576/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-06-30T12:34:00Z" timezone="America/New_York" class="datetime">Jun 30, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-expansion-reimbursement-agreement-nhs-england" hreflang="en">Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -CF patients in England will be among the first in Europe to benefit from access to KAFTRIO ® , if the medicine is approved by the European Commission - LONDON --(BUSINESS WIRE)--Jun. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-expansion-reimbursement-agreement-nhs-england" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27546/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-06-26T12:14:00Z" timezone="America/New_York" class="datetime">Jun 26, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/chmp-grants-positive-opinion-kaftrior" hreflang="en">CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease – – People 12 years of age and older who have two
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/chmp-grants-positive-opinion-kaftrior" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27541/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?items_per_page_toggle=1&amp;page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">First</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?items_per_page_toggle=1&amp;page=2" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">Previous</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=2" title="Go to page 3">
            <span class="visually-hidden">
              Page
            </span>3</a>
        </li>
              <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=3" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>4</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=4" title="Go to page 5">
            <span class="visually-hidden">
              Page
            </span>5</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=5" title="Go to page 6">
            <span class="visually-hidden">
              Page
            </span>6</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=4" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 151 - 200 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"items_per_page_toggle":"1","page":"3"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
